There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses the results from the Phase I CAR T-cell trial ZUMA-3 (NCT02614066) at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. These data show no difference in outcome or toxicity between patients who had previously been treated with blinatumomab and patients with other prior therapies. Dr Wierda gives an overview of the generally very positive results of the trial, which boasted 70% complete remission rates, as well as the general toxicities observed, such as cytokine release syndrome and neurotoxicity. Finally, he discusses future aims for the trial, including the expansion of the phase I study to examine the effects of a broader range of treatment concentrations.